The clinical impact of maternal COVID-19 on mothers, their infants, and placentas with an analysis of vertical transfer of maternal SARS-CoV-2-specific IgG antibodies is a study from the University of North Carolina at Chapel Hill. It is a preprint at medRxiv that came out yesterday.
The research included 115 pregnant mothers with COVID-19 from December 1, 2019, to May 31, 2021. All mothers are unvaccinated. (All texts are copied and pasted from the study.)
The results showed no congenital abnormalities in all infants including those from first or second trimester maternal COVID-19 infections.
There was no evidence of infant hearing loss or cardiovascular abnormalities conclusively linked to maternal SARS-CoV-2 infection.
All mothers and babies survived. One infant became infected with SARS-CoV-2 (0.87%).
Moderate and severe maternal COVID-19 were associated with increased cesarean section, premature delivery, infant neonatal intensive care unit admission, and maternal respiratory failure, and were more likely in Type 1 and Type 2 diabetic mothers.
Most placentas (n=63, 54.8%) showed normal or non-specific findings, while a subset had mild maternal vascular malperfusion (n=26, 22.6%) and/or mild microscopic ascending intrauterine infection (n=28, 24.3%).
In a small sample (n=10), the majority (90%) of maternal SARS-CoV-2 infections generated maternal SARS-CoV-2-specific IgG antibodies that were transferred to their infants, likely accounting for the low transmission of SARS-CoV-2 to infants during pregnancy and puerperium.
One mother in the study who did not develop an antibody response to SARS-CoV-2, had an infant infected with SARS-CoV-2. This suggests that the complete absence of generating maternal SARS-CoV-2-specific IgG antibodies increases the risk of infection of the infant by the mother.
Therefore, testing mothers and/or infants for these SARS-CoV-2 IgG antibodies may be warranted and considered as a part of the discussion with a mother deciding whether to room in with their infant while infected with SARS-CoV-2.
Most mothers with SARS-CoV-2 and their infants had a routine clinical course. Maternal SARS-CoV-2 infection was not associated with intrauterine fetal demise, infant death, congenital abnormalities, or hearing loss.
Infant infection with SARS-CoV-2 was rare and not via the placenta.
Most placentas had non-specific findings and a subset showed mild maternal vascular malperfusion and/or mild microscopic ascending intrauterine infection, which were not associated with maternal
COVID-19 severity.
After you read the study, please take time to listen to the short interview at this LINK about the 300% increase in miscarriages after the COVID jabs.
Knowing the risk and benefits of COVID-19 and the shots makes for better decision-making.
Don’t Get Sick!
Knowledge about Covid-19 is rapidly evolving. Stay current by subscribing. Feel free to share and like.
If you find value in the articles, please consider donating to show your support.
Reference: